These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36411463)

  • 1. Tumor-associated macrophages promote resistance of hepatocellular carcinoma cells against sorafenib by activating CXCR2 signaling.
    Wang HC; Haung LY; Wang CJ; Chao YJ; Hou YC; Yen CJ; Shan YS
    J Biomed Sci; 2022 Nov; 29(1):99. PubMed ID: 36411463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.
    Wan S; Zhao E; Kryczek I; Vatan L; Sadovskaya A; Ludema G; Simeone DM; Zou W; Welling TH
    Gastroenterology; 2014 Dec; 147(6):1393-404. PubMed ID: 25181692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. M2 macrophage exosomes promote resistance to sorafenib in hepatocellular carcinoma cells via miR-200c-3p.
    Li W; Zhao B; Wang Q; Lu J; Wu X; Chen X
    Int Immunopharmacol; 2024 Sep; 139():112807. PubMed ID: 39068757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells.
    Nour MA; Kheradmand F; Rasmi Y; Baradaran B
    Med Oncol; 2022 Aug; 39(11):165. PubMed ID: 35972579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
    Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
    J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma.
    Jing W; Shuo L; Yingru X; Min M; Runpeng Z; Jun X; Dong H
    Biochem Biophys Res Commun; 2019 Oct; 519(1):41-45. PubMed ID: 31481232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis.
    Al-Noshokaty TM; Mesbah NM; Abo-Elmatty DM; Abulsoud AI; Abdel-Hamed AR
    Life Sci; 2022 Aug; 303():120675. PubMed ID: 35640776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.
    Romito I; Porru M; Braghini MR; Pompili L; Panera N; Crudele A; Gnani D; De Stefanis C; Scarsella M; Pomella S; Levi Mortera S; de Billy E; Conti AL; Marzano V; Putignani L; Vinciguerra M; Balsano C; Pastore A; Rota R; Tartaglia M; Leonetti C; Alisi A
    J Exp Clin Cancer Res; 2021 Nov; 40(1):364. PubMed ID: 34784956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.
    Yurdacan B; Egeli U; Guney Eskiler G; Eryilmaz IE; Cecener G; Tunca B
    J Pharm Pharmacol; 2019 Jul; 71(7):1119-1132. PubMed ID: 31025377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
    Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
    Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary antioxidant quercetin overcomes the acquired resistance of Sorafenib in Sorafenib-resistant hepatocellular carcinoma cells through epidermal growth factor receptor signaling inactivation.
    Zhang Z; Wu H; Zhang Y; Shen C; Zhou F
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):559-574. PubMed ID: 37490119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
    Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
    Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
    Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy.
    Huang L; Xu R; Li W; Lv L; Lin C; Yang X; Yao Y; Saw PE; Xu X
    Acta Biomater; 2023 May; 162():98-109. PubMed ID: 36931417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.
    Shrestha R; Bridle KR; Cao L; Crawford DHG; Jayachandran A
    Curr Oncol; 2021 Jun; 28(3):2150-2172. PubMed ID: 34208001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression.
    Wu MH; Chiu YF; Wu WJ; Wu PL; Lin CY; Lin CL; Hsieh YH; Liu CJ
    Environ Toxicol; 2018 Dec; 33(12):1237-1244. PubMed ID: 30187994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization.
    Zhao X; Wang X; You Y; Wen D; Feng Z; Zhou Y; Que K; Gong J; Liu Z
    Exp Cell Res; 2020 Jun; 391(1):111979. PubMed ID: 32246992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma.
    Fan QM; Jing YY; Yu GF; Kou XR; Ye F; Gao L; Li R; Zhao QD; Yang Y; Lu ZH; Wei LX
    Cancer Lett; 2014 Oct; 352(2):160-8. PubMed ID: 24892648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of Anti-Proliferative and Apoptotic Effects of Sorafenib Using miR-27a Inhibitor in Hepatocellular Carcinoma Cell Lines.
    Abdel Wahab AHA; Ayad EG; Abdulla MS; Sharada HM; Ashmawy AM
    Asian Pac J Cancer Prev; 2021 Sep; 22(9):2951-2958. PubMed ID: 34582667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway.
    Chen S; Morine Y; Tokuda K; Yamada S; Saito Y; Nishi M; Ikemoto T; Shimada M
    Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.